Alnylam Pharmaceuticals | ALNY - Market Capitalization


Alnylam Pharmaceuticals reported $31.13B in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amgen USD 195.44B 5.55B Jun/2026
Arrowhead Research USD 11.5B 2.72B Jun/2026
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Incyte USD 22.65B 3.92B Jun/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 288.26B 25.18B Mar/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Sanofi EUR 113.52B 3.82B Mar/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Takeda JPY 8.2T 809.7B Jun/2026
Tectonic Therapeutic USD 580M 190M Mar/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026
Xencor USD 1.19B 301M Jun/2026